MX368268B - Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). - Google Patents

Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).

Info

Publication number
MX368268B
MX368268B MX2016004078A MX2016004078A MX368268B MX 368268 B MX368268 B MX 368268B MX 2016004078 A MX2016004078 A MX 2016004078A MX 2016004078 A MX2016004078 A MX 2016004078A MX 368268 B MX368268 B MX 368268B
Authority
MX
Mexico
Prior art keywords
cobicistat
atazanavir
treatment formulation
hiv treatment
formulations
Prior art date
Application number
MX2016004078A
Other languages
English (en)
Other versions
MX2016004078A (es
Inventor
May Yue Koo Otilia
Nikfar Faranak
Tao Jing
Kumar Kottala Niranjan
A Varia Sailesh
Original Assignee
Bristol Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51743576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX368268(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland
Publication of MX2016004078A publication Critical patent/MX2016004078A/es
Publication of MX368268B publication Critical patent/MX368268B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a las formulaciones de los compuestos contra el VIH, de atazanavir y cobicistat, y a los métodos de tratamiento que utilizan estas formulaciones.
MX2016004078A 2013-10-07 2014-10-06 Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). MX368268B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887574P 2013-10-07 2013-10-07
PCT/US2014/059310 WO2015054133A1 (en) 2013-10-07 2014-10-06 Hiv treatment formulation of atazanavir and cobicistat

Publications (2)

Publication Number Publication Date
MX2016004078A MX2016004078A (es) 2016-06-06
MX368268B true MX368268B (es) 2019-09-26

Family

ID=51743576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004078A MX368268B (es) 2013-10-07 2014-10-06 Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).

Country Status (28)

Country Link
US (2) US20160038502A1 (es)
EP (2) EP3054926B1 (es)
JP (2) JP6574415B2 (es)
KR (1) KR102286386B1 (es)
CN (1) CN106029058A (es)
AU (1) AU2014332200B2 (es)
BR (1) BR112016007526A8 (es)
CA (1) CA2926650A1 (es)
CL (1) CL2016000787A1 (es)
CY (1) CY1121105T1 (es)
DK (2) DK3421033T3 (es)
EA (1) EA031172B1 (es)
ES (2) ES2927484T3 (es)
HR (2) HRP20221126T1 (es)
HU (1) HUE059757T2 (es)
IL (1) IL244881B (es)
LT (2) LT3054926T (es)
MX (1) MX368268B (es)
MY (1) MY178960A (es)
PE (1) PE20160596A1 (es)
PL (2) PL3054926T3 (es)
PT (2) PT3054926T (es)
RS (2) RS57882B1 (es)
SA (1) SA516370891B1 (es)
SG (1) SG11201602501VA (es)
SI (2) SI3054926T1 (es)
SM (2) SMT201800507T1 (es)
WO (1) WO2015054133A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102917695A (zh) * 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
US20160038502A1 (en) * 2013-10-07 2016-02-11 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat
EP3368029A1 (en) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
ES2952878T3 (es) * 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
JP2003526671A (ja) * 2000-03-14 2003-09-09 レストラゲン，インコーポレイテッド 幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
WO2008037082A1 (en) * 2006-09-25 2008-04-03 Archer-Daniels-Midland Company Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
WO2009084086A1 (ja) * 2007-12-27 2009-07-09 Fujitsu Limited 通信システム，回線提供装置および通信方法
AU2009296734B2 (en) * 2008-09-25 2016-02-18 Cephalon Llc Liquid formulations of bendamustine
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
CN102917695A (zh) * 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
US20160038502A1 (en) * 2013-10-07 2016-02-11 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat

Also Published As

Publication number Publication date
EP3421033A1 (en) 2019-01-02
SI3421033T1 (sl) 2022-11-30
BR112016007526A8 (pt) 2020-03-03
PL3054926T3 (pl) 2018-12-31
DK3421033T3 (da) 2022-10-10
EP3421033B1 (en) 2022-07-27
PT3421033T (pt) 2022-09-23
EA031172B1 (ru) 2018-11-30
EP3054926B1 (en) 2018-07-25
MY178960A (en) 2020-10-26
SI3054926T1 (sl) 2018-10-30
LT3421033T (lt) 2022-11-10
ES2927484T3 (es) 2022-11-07
US20190358240A1 (en) 2019-11-28
IL244881B (en) 2021-12-01
DK3054926T3 (en) 2018-10-29
EP3054926A1 (en) 2016-08-17
HRP20181582T1 (hr) 2018-11-30
US20160038502A1 (en) 2016-02-11
SMT202200373T1 (it) 2022-11-18
MX2016004078A (es) 2016-06-06
HUE059757T2 (hu) 2023-01-28
LT3054926T (lt) 2018-11-12
RS63570B1 (sr) 2022-10-31
SA516370891B1 (ar) 2018-08-08
CN106029058A (zh) 2016-10-12
KR102286386B1 (ko) 2021-08-05
JP6574415B2 (ja) 2019-09-11
BR112016007526A2 (pt) 2017-08-01
EA201690594A1 (ru) 2016-09-30
AU2014332200A1 (en) 2016-05-19
PE20160596A1 (es) 2016-06-15
CA2926650A1 (en) 2015-04-16
SG11201602501VA (en) 2016-04-28
PT3054926T (pt) 2018-10-26
HRP20221126T1 (hr) 2022-11-25
CL2016000787A1 (es) 2016-11-25
WO2015054133A1 (en) 2015-04-16
IL244881A0 (en) 2016-05-31
JP2016532649A (ja) 2016-10-20
PL3421033T3 (pl) 2022-10-03
RS57882B1 (sr) 2019-01-31
SMT201800507T1 (it) 2018-11-09
JP2019011334A (ja) 2019-01-24
ES2693580T3 (es) 2018-12-12
CY1121105T1 (el) 2019-12-11
AU2014332200B2 (en) 2018-10-04
KR20160060764A (ko) 2016-05-30

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
ZA201708692B (en) Antibacterial compounds
MX378273B (es) Compuestos activos hacia bromodominios.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
PH12015501998A1 (en) Heterocyclic compounds and their uses
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2015012416A (es) Compuestos heterociclicos y sus usos.
CL2015002897A1 (es) Inhibidores de bace1
EP3003297A4 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
PH12017500836A1 (en) Transdermal formulations
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
MX2014015199A (es) Formulacion de pexiganan estable.
HK1217651A1 (zh) 固溶体组合物及其在剧痛中的用途
MX2016001694A (es) Formulacion de vacuna de sacarido.
UY35956A (es) Formulación de atazanavir y cobicistat para el tratamiento del vih
IN2013CH02437A (es)

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: INCYTE HOLDINGS CORPORATION

FG Grant or registration